Transition of Care. Группа авторов

of adults with 21-OHD can be achieved through a multidisciplinary approach. Future prospective studies designed specifically to examine the long-term effects of a successful transition of CAH patients are needed.

      Case History

      Salt-losing CAH due to 21-OHD was diagnosed in a female infant born with masculinization of her external genitalia (Prader III). She was compound heterozygous with an IVS2 splice mutation and a large lesion of the CYP21A2 gene. Medical treatment with GC and MC replacement was initiated. At 6 months of age, the patient underwent surgical reconstruction, including vaginoplasty. The patient has a regular follow-up and is doing well with GC and MC replacement therapy. She had regular linear growth at –0.5 SD. Breast development started at the age of 12 years and menarche at the age of 14, with regular menstrual cycles, without acne or hirsutism. The final height was 1.67 m for a target height at 1.69 m. The first gynecological evaluation was performed at the age of 15. Only a mild clitoromegaly was noted. She was referred to an adult endocrinologist at the age of 18. Her mother accompanied her for the first consultation. Compliance to replacement therapy was good, but the treatment was managed by her mother. The patient had understood that CAH is a genetically inherited lifelong disease, requiring long-term medication and follow-up. She was unable to self-manage stress doses of GC during illness, including self-administration of parenteral hydrocortisone. She did not know exactly about her surgical history and its physical implication. She presented a normal body mass index of 19.4, regular menstrual cycles, and mild acne. Hormonal assessment showed a good hormonal control of the disease. BMD showed a T score at –1.2 SD at the lumbar level and –1.4 SD at the femoral level. She was included into specific programs of therapeutic education on transition and CAH: the pediatric history was recalled, with a specific highlight on surgery, specific goals of medical management of CAH in adulthood were explained, sexuality and fertility were discussed, and autonomy was assessed. She had an appointment with a gynecologist and the psychologist of the department.

      During the follow-up, autonomy improved gradually. At the age of 19, she came alone to her medical appointment and was able to self-manage her treatment. This led to a transient period of poor hormonal control with irregular menstrual cycles and occurrence of hirsutism. The parents were worried about this and contacted the adult endocrinologist, but the compliance resumed quickly. At the age of 20, she began her sexual life and took combined oral contraception. Sexual intercourse was reported by the patient as satisfying. Regular follow-up showed a stabilization of BMD. At the age of 28, she came with her boyfriend to discuss their family plans and have genetic counseling. Her boyfriend did not carry mutations of the CYP21A2 gene. Optimized GC and MC regimes during fertility monitoring resulted in a spontaneous pregnancy. She delivered a healthy term newborn.

      Key Learning Points

      1.During transition, it is important to understand that CAH is a lifelong disease that is genetically inherited.

      2.The importance of a multidisciplinary follow-up throughout life and of treatment adherence should be emphasized.

      3.The patient has to be able to self-manage treatment.

      4.Regular monitoring of the efficacy of GC and MC replacement therapy, as well as periodic measurements and/or monitoring of weight, BMD, and CV risk factors should be carried out.

      5.On a regular basis, gonadic function, sexuality, and fertility should be assessed.

      6.Genetic counseling is warranted.

      7.Psychological support is also necessary.

      References

1Auchus RJ: The classic and nonclassic congenital adrenal hyperplasias. Endocr Pract 2015;21:383–389.

2Merke DP, Bornstein SR: Congenital adrenal hyperplasia. Lancet 2005;365:2125–2136.

3New MI, Abraham M, Gonzalez B, Dumic M, Razzaghy-Azar M, Chitayat D, Sun L, Zaidi M, Wilson RC, Yuen T: Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc Natl Acad Sci USA 2013;12:2611–2616.

4White PC, Speiser PW: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000;21:245–291.

5New MI: Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006;91:4205–4214.

6Bachelot A, Grouthier V, Courtillot C, Dulon J, Touraine P: Management of endocrine disease: congenital adrenal hyperplasia due to 21-hydroxylase deficiency: update on the management of adult patients and prenatal treatment. Eur J Endocrinol 2017;176:R167–R181.

7Auchus RJ, Arlt W: Approach to the patient: the adult with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2013;98:2645–2655.

8Finkielstain GP, Kim MS, Sinaii N, Nishitani M, Van Ryzin C, Hill SC, Reynolds JC, Hanna RM, Merke DP: Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2012;97:4429–4438.

9Bachelot A, Chakthoura Z, Rouxel A, Dulon J, Touraine P: Classical forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults. Horm Res 2008;69:203–211.

10Auchus RJ: Management considerations for the adult with congenital adrenal hyperplasia. Mol Cell Endocrinol 2015;408:190–197.

11Charmandari E, Brook CG, Hindmarsh PC: Classic congenital adrenal hyperplasia and puberty. Eur J Endocrinol 2004;151:U77–U82.

12Ross RJ, Rostami-Hodjegan A: Timing and type of glucocorticoid replacement in adult congenital adrenal hyperplasia. Horm Res 2005;64(suppl 2):67–70.

13Bonfig W, Bechtold S, Schmidt H, Knorr D, Schwarz HP: Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty. J Clin Endocrinol Metab 2007;92:1635–1639.

14Charmandari E, Johnston A, Brook CG, Hindmarsh PC: Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Endocrinol 2001;169:65–70.

15Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, Hahner S, Han TS, Carroll PV, Conway GS, Rees DA, Stimson RH, Walker BR, Connell JM, Ross RJ; the United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE): Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab 2010;95:5110–5121.

16Finkielstain GP, Kim MS, Sinaii N, Nishitani M, Van Ryzin C, Hill SC, Reynolds JC, Hanna RM, Merke DP: Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab